Since its establishment, Devicare has been a pioneer in the development of innovative medical treatments in urology thanks to the combination of applying the latest scientific advances in nutritional therapies with the latest digital technologies.
Last news about Devicare
Devicare announces Collaboration with Idneo for the Development and Manufacture of Lit-Control® In Vitro Diagnostic Devices
Devicare ha anunciado una colaboración estratégica con Idneo Technologies S.A.U. para desarrollar y fabricar innovadores dispositivos self test de diagnóstico in vitro que se comercializan bajo la marca Lit-Control® de Devicare. Según los términos del acuerdo, Devicare transferirá a Idneo la fabricación del dispositivo médico Lit-Control® pH Meter, que forma parte de la actual familia…
Successful Ventures invierte en Devicare. La red de Business Angels liderada por Fran Piera, Ot Vila y Dani Romy, que actualmente cuenta con más de 100 inversores activos y que en 2019 invirtió 1,8 MM € en 15 startups de base tecnológica, comienza su andadura en el sector e-health de la mano de la empresa…
The results show the efficacy and tolerance of its products Lit-Control® pH Up and Lit-Control® pH Down to regulate urinary pH in patients with renal lithiasis. The study confirms that maintaining urinary pH within the appropriate range (between 5.5 and 6.2 pH) decreases the likelihood of new events related to kidney stones from appearing by more than 50%.
The IMB-CNM-CSIC has successfully passed the inspection from the AEMPS and will now be an authorised sub-contractor for Devicare
The Microelectronic Institute of Barcelona-National Microelectronic Centre (IMB-CNM), one of Devicare's leading suppliers, has successfully passed an inspection of its facilities by the Spanish Agency of Medicines and Medical Devices (AEMPS). The ICB-CNM is now accredited as an authorised sub-contractor by the AEMPS to carry out its activity in the medical devices sector.
Devicare, with headquarters in the UAB Research Park, has recently announced business agreements in United States, United Kingdom, Malta and Algeria and is now present in 34 countries. The company has 5 products on the market (a medical device and dietary supplements), 49 patents, 6 clinical trials and 9 scientific publications.
Devicare participates in the leading lithiasis event in Spain and presents the results of the 'Double J' trial
Devicare participated in the National Meeting of the Lithiasis, Endourology, Laparoscopy and Robotics Groups (LELR), held on 24 and 25 January in Palma de Mallorca. The plenary sessions focused on the medical and surgical handling of urinary lithiasis which affects 10% of the Spanish population. The final results of the “Double J” clinical trial led by specialists from nine leading Spanish hospitals renowned for urology care and sponsored by Devicare were also presented during the event.
Dr Carlos Torrecilla, director of the Lithiasis Unit of the Bellvitge University Hospital and national coordinator of the Lithiasis and Endourology Group of the Spanish Association of Urology, is the principal investigator of a clinical trial sponsored by Devicare conducted in nine Spanish university hospitals (Bellvitge, La Paz, Río Hortega, Puigvert Foundation, San Cecilio, Valme, Álvaro Cunqueiro, La Fe and Santiago de Compostela)...
The multinational company Exeltis and the digital therapeutics company Devicare have signed an agreement to market the Lit-Control® family of products in Spain. Lit-Control® is the world's first digital therapeutics solution that allows the most common urological diseases to be prevented and treated effectively from home while also improving patients' adherence to the treatment. This collaboration brings together Exeltis' expertise and excellence in health care with Devicare's experience in product development, intellectual property and clinical research...
Devicare promotes a pioneering clinical trial to prevent the calcification of double J stent catheters
Devicare and nine leading hospitals in urology have started the pioneering international "Double J" study to evaluate the combined use of a medical device and a nutraceutical in controlling urinary pH and inhibiting crystallisation in order to prevent the calcification of double J stent catheters and reduce the number of associated complications.